03 - Sağlık ve Kaliteli Yaşam

Goal:
03 - Sağlık ve Kaliteli Yaşam

Description

AMAÇ 3: SAĞLIKLI BİREYLER Çocuk ölüm oranlarının azaltılması, anne sağlığının iyileştirilmesi, HIV/AIDS, sıtma ve diğer hastalıklar ile mücadelede büyük aşama kaydetmiş durumdayız. 1990 yılından bu yana, önlenebilir çocuk ölümlerinde dünya genelinde %50’yi aşan azalma olmuştur. Anne ölümleri de dünya genelinde %45 azalmıştır. 2000 ile 2013 arasında HIV/AIDS bulaşma oranı %30 azalmış, 6,2 milyonu aşkın insan sıtmadan kurtarılmıştır. Bu ölümler; önleme ve tedavi, eğitim, aşı kampanyaları, cinsel ve üreme sağlığı hizmetleri vasıtasıyla önlenebilir. Sürdürülebilir Kalkınma Amaçları; AIDS, verem, sıtma ve diğer bulaşıcı hastalık salgınlarını 2030 yılına kadar ortadan kaldırmaya yönelik cesur bir taahhüttür. Amaç, herkesin genel sağlık hizmeti, güvenli ve erişilebilir ilaç ve aşıya kavuşmasını sağlamaktır. Aşı araştırma ve geliştirmelerinin desteklenmesi, bu sürecin vazgeçilmez bir parçasıdır.

Full item page

Publication Search Results

Now showing 1 - 8 of 8

Open Access
OPTIMIZATION OF NUCLEIC ACID BINDING TO MAGNETIC PARTICLES WITH THE AIM OF DETECTION OF DANGEROUS VIRUSES
(2021-01-01T00:00:00Z) Banas, Dominik; Rychly, Ondrej; Salmistraro, Stefano; Aksu, Ahmet Davut; Krzyzankova, Miroslava; Kizek, Rene
African Swine Fever Virus (ASFV) is a DNA virus of the Asfivirus genus of the Asfarviridae family that is found in blood, body fluids, and internal organs. ASFV was described more than 40 years ago. This virus spreads pandemically and the mortality rate of the virus-related disease ranges from 90 to 100 %. The aim of this study was to propose the detection of specific nucleic acid of ASFV using electrochemical hybridization biosensor. Determination of DNA was conducted by AdTSV DPV a CV (potential 0 V, end potential -1.8 V, step potential 5 mV, modulation amplitude 25 mV, 0.2 M acetate buffer pH 5.0). The volume of analysed sample was 10 mu L. CV signals CA (log -0.0373x, r 0.99, Ep -1.30 V) and P peak (log -0.0801x, r 0.99, Ep -1.52 V) were observed. To increase the sensitivity, a modification of ODN with CdTe was proposed. The CdTe signal was observed around the potential of -0.56 V and for modified ODNs the signal was -0.58 V. SPION were prepared to capture DNA. The interaction of DNA (PCR fragment, 280 bp) with SPION was very fast within 30 s. The technique will be further used for a microfluidic system.
Open Access
EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
(2020-09-01T00:00:00Z) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; ÖZGÜROĞLU, Mustafa; Gogishvili, M.; TÜRK, HACI MEHMET; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; TÜRK, HACI MEHMET
Open Access
Efficacy and tolerability of first-line chemotherapy in elderly patients ( age >= 70 years) with metastatic gastric cancer: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)
(2016-10-01T00:00:00Z) Aldemir, M. N.; Turkeli, M.; Hacioglu, B.; Sakin, A.; Yaman, E.; Coban, E.; Koca, D.; Karaca, M.; Simsek, M.; Bahceci, A.; Sen, E.; Eren, T.; Aliustaoglu, B. O.; Sakalar, T.; Kalkan, N. O.; Aktas, G.; Bilici, M.; Turhal, S.; Benekli, M.; Tekin, S. B.
Open Access
Evaluating compliance to stimulants in adults with attention deficit and hyperactivity disorder
(2021-12-03T00:00:00Z) Kılıç, Özge; Boylu, Muhammed Emin; KILIÇ, ÖZGE; BOYLU, MUHAMMED EMİN
Objective: Attention deficit hyperactivity disorder (ADHD) has several negative psychosocial outcomes including poor work performance, academic failure, problems in social relationships, and criminality. However, it is among the most treatable mental disorders given the safety and efficacy of stimulants. We aimed to explore compliance levels to methylphenidate and associated sociodemographic factors in adults with ADHD.Methods: Patients with ADHD who have been following up in a single-center outpatient psychiatry clinic of a university hospital were included in the study. Diagnoses were established according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) during a face-to-face clinical interview. Sociodemographic data form and Morisky medication adherence scale were utilized.Results: Among 64 patients (36 males, 28 females) (mean age ± SD = 25.2 ± 6.8) with ADHD, 19 (29.7 %) and 29 (45.3%) patients showed high and medium adherence to methylphenidate respectively. However, 16 (25 %) had low adherence. Men and women did not significantly differ in compliance levels to stimulants (X2 (2) = 1.639, p = 0.441). Compliance was not found to be related to education, marital and economic status, living conditions, smoking. The number of patients who consume alcohol tends to be higher in the low adherent group although not reaching statistical significance.Discussion: One-fourth of adult patients with ADHD had low adherence to methylphenidate. Men and women did not differ in adherence levels. No significant difference has been observed in the mean ages between the three adherence groups. Our results were in line with some earlier studies on treatment adherence in ADHD but not with others that showed adherence was higher in females and younger patients. The reason for these discrepancies could be that the studies with contrary results have recruited both children and adolescents. Longitudinal multicenter studies are needed to draw conclusions on the factors affecting compliance in ADHD.Keywords: attention deficit and hyperactivity disorder, drugs/medication, pharmacology, treatment compliance, treatment adherence, demographic
Open Access
POSSIBLE POTENTIAL INTERACTIONS BETWEEN OBESITY, QUALITY OF LIFE, PSYCHOLOGICAL STATUS AND CLINICAL PARAMETERS IN PSORIATIC ARTHRITIS
(2019-06-01T00:00:00Z) Gok, Kevser; Nas, Kemal; Kilic, Erkan; Sargin, Betul; Kasman, Sevtap Acer; Alkan, Hakan; Sahin, Nilay; CENGİZ, Gizem; Cuzdan, Nihan; Gezer, Ilknur Albayrak; Keskin, Dilek; Mulkoglu, Cevriye; Resorku, Hatice; Sunar, Ismihan; Hasturk, Ajda Bal; Duruoz, Mehmet Tuncay; Kucukakkas, Okan; YURDAKUL, OZAN VOLKAN; Melikoglu, Meltem Alkan; Aydin, Yildiray; Ayhan, Figen; Bodur, Hatice; Calis, Mustafa; Capkin, Erhan; Devrimsel, Gul; Hizmetli, Sami; Kamanli, Ayhan; Keskin, YAŞAR; Kocabas, Hilal; Kutluk, Oznur; Sen, Nesrin; Sendur, Omer Faruk; Tekeoglu, Ibrahim; Toprak, Murat; Tolu, Sena; Tuncer, Tiraje; YURDAKUL, OZAN VOLKAN; KESKİN, YAŞAR
Open Access
EFFICACY OF ADJUVANT 9-WEEKS TRASTUZUMAB IN NODE-NEGATIVE T1A/B HER2-POSITIVE BREAST CANCER
(2014-09-01T00:00:00Z) Sendur, M. A.; Aksoy, S.; Uncu, D.; Demir, H.; Yuksel, S.; Ekinci, A. S.; Kaplan, A.; Ustaalioglu, B. B.; Tufan, G.; Inanc, M.; Ozdemir, N.; Artac, M.; Tastekin, D.; Kacan, T.; Oguz, A.; Arpaci, E.; Yazilitas, D.; Gumus, M.; Zengin, N.; Altundag, M. K.
Aim: The benefit of the addition of 9-weeks or 52-weeks adjuvant trastuzumab to chemotherapy compared with chemotherapy alone was shown in five randomized trials. Despite retrospective series having shown the poor prognosis of HER2-positive T1a/b node-negative tumors, the efficacy of adjuvant trastuzumab was not known exactly. The aim of this study is to evaluate the efficacy of trastuzumab in HER2-positive T1abN0M0 breast cancer. Methods: Newly diagnosed 705 T1a/b node-negative breast cancer patients from July 2000 to December 2013 in 13 clinics were retrospectively analyzed; a total of 166 HER2-positive patients were included in this study. In this study 54 (32.5%) patients were treated with adjuvant trastuzumab, whereas 112 (67.5%) patients were not treated with adjuvant trastuzumab. Demographic and medical data including age, performance status, tumor characteristics and comorbid diseases were collected from the medical charts. Kaplan–Meier survival analysis was carried out for DFS and OS. Results: The median age of the study population was 53 (24-79) years. Median follow up was 37 (2-157) months. Baseline demographic characteristics of both groups were similar and non-significant. In both treatment groups, median age, histology, menopausal status lymphovascular invasion and perineural invasion positivity were similar. But in trastuzumab treatment group grade 3 tumors were significantly higher compared with non-trastuzumab arm (55.1% vs 26.0%, P = 0.002). Also in trastuzumab treatment arm, combination chemotherapy (P < 0.001) were significantly used more than non-trastuzumab arm, whereas hormonal treatment (P = 0.002) were used significantly higher in non-trastuzumab arm. Median DFS and OS could not be obtained due to the low events in both groups. With a 37 months follow up, recurrence was observed only one patient (1.8%) in trastuzumab arm and 3 patients (3.6%) in non-trastuzumab arm. No exitus was observed during the follow-up period. Conclusions: In retrospective series, patients with HER2-positive T1abN0M0 tumors have a significant risk of relapse and recurrence. But in our study, due to the low events no comment can be made with 9-weeks adjuvant trastuzumab. Future studies with longer follow-up are needed to show the efficacy of adjuvant trastuzumab in HER2-positive T1abN0M0 breast cancer.
Open Access
THE EVALUATION OF CELLULAR AND HUMORAL IMMUNITY CHARACTERISTICS IN GASTROINTESTINAL AND HEPATOCELLULAR CANCERS
(2014-06-01) KURSAS, Turkdogan; Huriye, Kiziltan; AYSE, Gunes Bayir; YUSUF, Kayar; HAKAN, Senturk; TUZUN, Ince Ali; ORHAN, Kocaman; AHMED, Danalioglu; KIZILTAN, HURİYE ŞENAY
Introduction: Gastrointestinal cancers (GI Ca) are a global health problem leading to high morbidity and mortality all over the world. Human organism presents a well organised defense mechanism against cancer cells by humoral and cellular immune system. Nowadays, cancer immunotherapy is an essential and promising research field of modern immunology. In this study, we aimed to evaluate the characteristics of the humoral and cellular immune systems in gastrointestinal and hepatocellular cancers (HCC) patients. Methods: Cellular and humoral immune parameters (CD3, CD4, CD8, CD16 / CD56 and CD 19 lymphocytes respectively) were investigated in the peripheral blood samples of 71 gastric Ca, 50 pancreatic Ca, 27 colorectal Ca, 50 HCC patients and of 30 healthy persons as control group by flow cytometry method. One way Anova and post hoc Dunnett tests were used to compare mean lymphocyte values of cancer groups with the control group. Significance level is determined as p: 0.05. Results: CD3 and CD4 lymphocyte levels were not significantly different in all cancer groups compared to the control group (Table-1). CD8 lymphocyte levels were significantly increased in pancreatic and colorectal cancer groups (p < 0.05) whereas CD19 lymphocytes were significantly lower in the same groups (p < 0.01-0.05). Natural killer (CD16 / CD56) lymphocytes were significantly higher in gastric Ca, colorectal Ca and HCC patients compared to the control group (p < 0.01-0.05).
Open Access
Utility of the Neutrophil to Lymphocyte Ratio in Predicting In-hospital Mortality in Patients That Received Levosimendan Treatment for Acute Decompensated Heart Failure
(2013-10-01T00:00:00Z) Tasal, Abdurrahman; Surgit, Ozgur; BACAKSIZ, AHMET; Goktekin, Omer; Uyarel, Huseyin; Ergelen, Mehmet; Erdogan, Ercan; Kul, Seref; Sonmez, Osman; Turfan, Murat; Kucukbuzcu, Sitki; Vatankulu, Mehmet Akif; YAMAÇ, AYLİN HATİCE; BACAKSIZ, AHMET; YAMAÇ, AYLİN HATİCE
Aim The aim of the study was to investigate the effect of levosimendan infusion on hematological variables in patients with acute heart failure. Also, predictive value of these variables over in hospital mortality evaluated. Methods Two hundred and nineteen patients (168 male, 51 female, mean age 63.2±12.7 years) with acute exerbation of advanced heart failure (ejection fraction ≤35%) were included in this study. Levosimendan was initiated as a bolus of 6 μg/kg followed by a continuous infusion of 0,1 μg/kg/min for 24 hours. Changes of hematological variables between admission and on third day after levosimendan infusion were evaluated. Categorical variables were expressed as frequencies and percentages. Continuous variables were compared using analysis of variance and Kruskal-Wallis tests for those with normal and skewed distributions, respectively. Chi-square tests were used to compare categorical variables. Univariate and multivariate Cox regression models were used to evaluate the independent association of different hematological variables with in-hospital mortality. Results Table 1 demonstrated the baseline demographical and laboratory characteristics of the patients. After levosimendan therapy, significant decrease in WBC and neutrophil counts and increase in lymphocyte count. As a result, neutrophil to lymphocyte ratio (NLR) decreased. Compared to patients that survived, in patients who died during in-hospital stay, these hematological changes not occurred ( Table 2 ). Δ NLR detected as independent predictor of in hospital mortality when other hematological variables associated with mortality analysed in the multivariate logistic regression analysis (R2=0.094, p=0.003). Conclusion Our study showed that levosimendan treatment is associated with significant changes in hematological variables in patients with acute exacerbation of advanced heart failure. The difference between baseline and post-treatment NLR is independent predictor of in hospital mortality.